Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARV-1801 plus intravenous ceftazidime or meropenem for hospitalized adults with melioidosis
ISRCTN14019371Phase 2Completed
- Sponsor
- Arrevus
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in melioidosis comparing ARV-1801 plus intravenous antibiotic with Placebo plus intravenous antibiotic (2 arms). Primary endpoint: All-cause in-hospital mortality in modified intent-to-treat population at Day 14. Started May 2022; status: completed.
02
Drugs
ACG-701
03
Conditions
melioidosis
Beyond the preview
Go deeper on ISRCTN14019371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14019371.